Naslov
Influence of quality of life on adherence to adjuvant endocrine therapy in women with early breast cancer

Autori
Dugonjić Okroša, A. ; Silovski, T. ; Dedić Plavetić, N. ; Mucalo, I.

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Pharmaca / Mršić-Pelčić, J. ; Vitezić, D. ; Janković, T. - , 2022, 102-102

Skup
10. HRVATSKI KONGRES FARMAKOLOGIJE I 1. HRVATSKI KONGRES KLINIČKE FARMAKOLOGIJE S MEĐUNARODNIM SUDJELOVANJEM

Mjesto i datum
Opatija, Hrvatska, 22.09.2022. - 25.09.2022

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
breast cancer, endocrine treatment, AET

Sažetak
Introduction High survival rate in early breast cancer is a direct consequence of highly effective adjuvant endocrine treatment (AET) recommended to be taken 5 to 10 years. However, AET has numerous side effects that adversely affect the quality of life (QoL) and preclude long-term adherence. This study aimed to investigate the Qo Linearly-stage breast cancer in women receiving AET and to explore its association with adherence. Materials and methods This cross-sectional study included women with early hormone-dependent breast cancer treated with AET for more than 3 months. There search was conducted at the University Hospital Centre (UHC) Zagreb. Validated instruments, the Medication Adherence Report scale(MARS-5) and the Functional Assessment of Cancer Therapy, endocrine symptoms- FACT-ES, were used. The collected data were processed and presented with descriptive statistics and an independentt-test. Results Overall, 329 respondents completed the survey. In line with the MARS score participants were divided into 4 groups: 56.3% of adherers (taking all indicated doses), unintentional non- adherers(26.3%), intentionalnon-adherers(3.9%) andintentional/unintentionalnon-adherers(13.5%). Total QoL score was generally high (score range 138-146 out of 184) and not significantly different between the groups (t-test, p<0.05). TheFACT-E S endocrine symptom subscale(ESS)score was statistically lower among intentional non- adherers (t=1.86, p=0.03) and intentional/unintentionalnon-adherers (t=2.26, p=0.01) as opposed to adherers. Conclusions QoL was generally high and similar across participants indicating that adherence to therapy is not associated with the overall QoL. However, the ESS score indicated a high eradverse effects burden, hence rendering participants intentionally non-adherent. Further investigation of specific adverse events and their association with adherence could shed light on possible intervention targets for adherence behaviour change.

Izvorni jezik
Engleski

Znanstvena područja
Farmacija

POVEZANOST RADA